Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
Heart Test Laboratories Inc. Warrant (HSCSW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/31/2025: HSCSW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -62.5% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/31/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 2.58 | 52 Weeks Range 0.04 - 0.17 | Updated Date 03/20/2025 |
52 Weeks Range 0.04 - 0.17 | Updated Date 03/20/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.09 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -62.95% | Return on Equity (TTM) -163.47% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 995735 |
Shares Outstanding - | Shares Floating 995735 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Heart Test Laboratories Inc. Warrant
Company Overview
History and Background
Heart Test Laboratories Inc. is a medical device company focused on developing and commercializing a non-invasive cardiac stress test. The company's primary product is the MyoStrainu00ae system, designed to assess myocardial strain. The warrant represents the right to purchase shares of Heart Test Laboratories Inc. common stock at a specified price.
Core Business Areas
- Cardiac Diagnostics: Development and commercialization of innovative non-invasive cardiac diagnostic solutions, primarily the MyoStrainu00ae system for myocardial strain analysis.
Leadership and Structure
Information on the specific leadership team and detailed organizational structure of Heart Test Laboratories Inc. is not readily available for this warrant-specific analysis. The warrant's structure is defined by its terms, including exercise price and expiration date.
Top Products and Market Share
Key Offerings
- MyoStrainu00ae System: A non-invasive diagnostic device designed to measure myocardial strain, offering a potentially more sensitive assessment of cardiac function compared to traditional methods like echocardiography. Market share data for this specific product is not publicly available at this time. Key competitors in the broader cardiac diagnostics market include companies offering ECG, stress echocardiography, and other cardiac imaging solutions.
Market Dynamics
Industry Overview
The cardiac diagnostics market is a significant segment within the broader medical device industry, driven by the rising prevalence of cardiovascular diseases and the demand for earlier and more accurate diagnostic tools. Technological advancements are leading to the development of non-invasive and more quantitative assessment methods.
Positioning
Heart Test Laboratories Inc. aims to position its MyoStrainu00ae system as a differentiated offering in the cardiac diagnostics space, emphasizing its non-invasive nature and potential for superior diagnostic accuracy in strain assessment. Its competitive advantage lies in its novel approach to measuring myocardial strain.
Total Addressable Market (TAM)
The TAM for cardiac diagnostics is substantial and growing, driven by aging populations and increasing cardiovascular disease burden globally. Heart Test Laboratories Inc. is positioned to capture a segment of this market by offering a specialized solution for myocardial strain analysis.
Upturn SWOT Analysis
Strengths
- Proprietary technology for myocardial strain measurement.
- Focus on non-invasive diagnostics.
- Potential for improved diagnostic accuracy in certain cardiac conditions.
Weaknesses
- Relatively new to the market with limited commercial adoption and brand recognition.
- Dependence on successful regulatory approvals and market acceptance.
- Limited financial resources compared to established medical device giants.
Opportunities
- Growing demand for advanced cardiac diagnostic tools.
- Potential partnerships with cardiology practices and hospitals.
- Expansion into international markets.
- Further development and application of MyoStrainu00ae technology.
Threats
- Competition from established players with existing market share and distribution channels.
- Stringent regulatory hurdles for medical devices.
- Reimbursement challenges for new diagnostic technologies.
- Rapid technological advancements that could render current technology obsolete.
Competitors and Market Share
Key Competitors
- GE Healthcare (GE)
- Siemens Healthineers (SEMHF)
- Philips Healthcare (PHG)
- Cardiovascular Systems Inc. (CSII) - primarily in interventional cardiology, but relevant in the broader cardiovascular space.
- Abbott Laboratories (ABT) - offers a range of cardiac devices and diagnostics.
Competitive Landscape
Heart Test Laboratories Inc. operates in a highly competitive landscape dominated by large, well-established medical device manufacturers. Its success hinges on demonstrating the clinical and economic superiority of its MyoStrainu00ae system to gain traction against established diagnostic modalities.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trajectory is primarily associated with the progress of Heart Test Laboratories Inc. in developing and seeking market approval for its MyoStrainu00ae system. This includes milestones in research, development, and clinical trials.
Future Projections: Future projections are speculative and depend on the successful commercialization of the MyoStrainu00ae system, market adoption, and the company's ability to secure further funding and navigate regulatory pathways. Analyst estimates for the underlying company, if available, would provide further insight.
Recent Initiatives: Recent initiatives would likely focus on product development, clinical validation, regulatory submissions, and early-stage commercialization efforts for the MyoStrainu00ae system.
Summary
Heart Test Laboratories Inc. Warrant represents an investment in a company developing a novel cardiac diagnostic technology. The company's core strength lies in its proprietary MyoStrainu00ae system, aiming to provide a non-invasive measure of myocardial strain. However, it faces significant challenges from established competitors and regulatory hurdles. Its success is contingent on market adoption and the ability to overcome financial and commercialization obstacles.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company press releases and investor relations materials (where available for Heart Test Laboratories Inc.).
- Industry research reports on cardiac diagnostics.
- Financial data aggregators for competitor information.
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute financial advice. Warrants are complex financial instruments with a high degree of risk. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions. Market share data for Heart Test Laboratories Inc.'s specific product is an estimation based on its competitive positioning.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Heart Test Laboratories Inc. Warrant
Exchange NASDAQ | Headquaters Southlake, TX, United States | ||
IPO Launch date 2022-06-15 | CEO, President & Chairman of the Board of Directors Mr. Andrew Simpson | ||
Sector Healthcare | Industry Medical Devices | Full time employees 15 | Website https://heartsciences.com |
Full time employees 15 | Website https://heartsciences.com | ||
HeartSciences Inc., a medical technology company, focuses on applying AI-based technology to an ECG to enhance its clinical utility. It is developing artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction caused by heart disease and/or age-related cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related to cardiac dysfunction and conventional ECG information in the same test; and MyoVista Insights, a cloud-based platform to host AI-ECG algorithms on an ECG hardware agnostic basis. The company was formerly known as Heart Test Laboratories, Inc. and changed its name to HeartSciences Inc. in October 2024. HeartSciences Inc. was incorporated in 2007 and is headquartered in Southlake, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.